Morgan Stanley Lowers CME Group Price Target to $319.00

Research analysts at Morgan Stanley have revised their price target for CME Group (NASDAQ:CME), lowering it from $320.00 to $319.00. The adjustment was detailed in a research note issued to investors on Thursday, indicating that the firm maintains an “overweight” rating on the financial services provider’s stock. This new target price suggests a potential upside of approximately 16.47% from CME Group’s current trading price.

Several other financial institutions have also provided updates on CME Group’s stock. Jefferies Financial Group reduced its target from $313.00 to $304.00, maintaining a “buy” rating. On January 5, Raymond James Financial raised its target from $307.00 to $311.00, while reiterating an “outperform” rating. Conversely, UBS Group upheld a “neutral” stance in their assessment on January 6. Additionally, Rothschild & Co Redburn increased its price objective from $297.00 to $300.00 with a “neutral” rating. Weiss Ratings also reaffirmed a “buy (b+)” rating on December 29.

Despite the mixed ratings, overall sentiment is reflected in a consensus rating of “Hold” among analysts, with an average target price of $291.88, according to data from MarketBeat.com.

Recent Earnings Performance

CME Group reported its latest quarterly earnings on October 22, revealing earnings per share (EPS) of $2.68. This figure exceeded analysts’ consensus estimate of $2.63 by $0.05. The company’s revenue for the quarter reached $1.54 billion, slightly below expectations of $1.56 billion. Year-over-year, the company experienced a 3.0% decline in revenue, as it reported the same EPS of $2.68 during the same quarter the previous year. Analysts anticipate that CME Group will achieve an EPS of $10.49 for the current fiscal year.

Insider Activity and Institutional Holdings

In related developments, insider trading activity has raised eyebrows. Director Harold Eugene Jr. Ford sold 1,000 shares of CME Group on November 3, generating a total of $263,530.00 at an average price of $263.53. Following this transaction, Ford’s ownership in the company decreased by 47.82%. The sale was reported in a legal filing with the U.S. Securities and Exchange Commission (SEC).

Additionally, CEO Terrence A. Duffy disposed of 25,000 shares on December 11, realizing $6,738,750.00 at an average price of $269.55. Duffy now holds 65,804 shares, reflecting a 27.53% decrease in ownership. Approximately 0.30% of CME Group’s stock is owned by corporate insiders.

Institutional investors continue to play a significant role in CME Group’s stock structure. Caldwell Trust Co increased its stake by 116.3% in the third quarter, owning 93 shares valued at $25,000. Meanwhile, Highline Wealth Partners LLC boosted its position by 84.3%, acquiring 94 shares for $26,000. Other firms, including Loring Wolcott & Coolidge Fiduciary Advisors LLP and Financial Consulate Inc., have also made new investments, highlighting growing institutional interest.

Overall, hedge funds and institutional investors hold 87.75% of CME Group’s stock, underscoring the company’s solid backing from larger financial entities.

CME Group, known for operating major derivatives exchanges like the Chicago Mercantile Exchange and the New York Mercantile Exchange, continues to be a key player in the global financial markets, offering a wide range of futures and options contracts across various asset classes.